医学
药品
药物输送
肺癌
药理学
不利影响
吸入
生物利用度
干粉吸入器
靶向给药
癌症
吸入器
肿瘤科
内科学
麻醉
哮喘
化学
有机化学
作者
Nazrul Islam,Derek J. Richard
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2019-02-14
卷期号:19 (3): 162-178
被引量:12
标识
DOI:10.2174/1568009618666180525083451
摘要
Local delivery of drug to the target organ via inhalation offers enormous benefits in the management of many diseases. Lung cancer is the most common of all cancers and it is the leading cause of death worldwide. Currently available treatment systems (intravenous or oral drug delivery) are not efficient in accumulating the delivered drug into the target tumor cells and are usually associated with various systemic and dose-related adverse effects. The pulmonary drug delivery technology would enable preferential accumulation of drug within the cancer cell and thus be superior to intravenous and oral delivery in reducing cancer cell proliferation and minimising the systemic adverse effects. Site-specific drug delivery via inhalation for the treatment of lung cancer is both feasible and efficient. The inhaled drug delivery system is non-invasive, produces high bioavailability at a low dose and avoids first pass metabolism of the delivered drug. Various anticancer drugs including chemotherapeutics, proteins and genes have been investigated for inhalation in lung cancers with significant outcomes. Pulmonary delivery of drugs from dry powder inhaler (DPI) formulation is stable and has high patient compliance. Herein, we report the potential of pulmonary drug delivery from dry powder inhaler (DPI) formulations inhibiting lung cancer cell proliferation at very low dose with reduced unwanted adverse effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI